The Definitive Guide to DuP-697
All enrolled individuals who gained at the least a person dose of zosuquidar or placebo through induction were monitored for your incidence of adverse situations (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions ended up related to the duration of prolonged and major myelosuppression as is expected with induction